Colorectal Cancer Reagents

Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide. Molecular characterization — RAS/RAF status, microsatellite instability (MSI), and immune checkpoint expression — is essential for treatment selection. abinScience provides reagents targeting KRAS, BRAF, MMR proteins (MLH1/MSH2/MSH6/PMS2), CEA, EGFR, and PD-1/PD-L1 for CRC research and biomarker validation. RUO

Key Biomarkers & Targets

KRAS / BRAF

RAS-MAPK Pathway

KRAS mutations in ~45% of CRC; BRAF V600E in ~10%. Critical for anti-EGFR eligibility. 160+ combined antibodies and proteins.

Antibodies • Proteins

MSI / MMR Panel

MLH1, MSH2, MSH6, PMS2

MSI-H/dMMR status predicts checkpoint inhibitor response. Antibodies available for all four MMR proteins.

Antibodies

CEA

CEACAM5 / CD66e

Gold-standard serum biomarker for CRC recurrence monitoring. Also emerging bispecific and ADC target. 100+ products.

Antibodies • Biosimilars

EGFR

ErbB1 / HER1

Cetuximab/panitumumab target in RAS wild-type CRC. 180+ antibodies and biosimilar-grade reference proteins.

Antibodies • Proteins • Biosimilars

PD-1 / PD-L1

CD279 / CD274

Pembrolizumab first-line for MSI-H/dMMR CRC. 260+ combined checkpoint antibodies, proteins, and biosimilars.

Antibodies • Proteins • Biosimilars

VEGF / HER2

Angiogenesis & Amplification

Bevacizumab backbone in CRC regimens; HER2 amplification in ~3% guides trastuzumab + pertuzumab. 300+ combined products.

Antibodies • Proteins • Biosimilars

Why Researchers Choose abinScience for CRC

Complete RAS/RAF ProfilingKRAS, NRAS, and BRAF antibodies for WB and IHC to characterize MAPK pathway activation and anti-EGFR resistance in CRC.

MSI/MMR IHC PanelMLH1, MSH2, MSH6, PMS2 antibodies available. See product pages for validated applications.

CEA Monitoring ToolsAnti-CEA antibodies with ELISA and IHC validation, plus research-grade CEA biosimilar proteins.

Protein–Antibody–Kit WorkflowSame target as recombinant protein, detection antibody, and ELISA kit from one manufacturer for streamlined assay development.

Original Manufacturer PricingDirect-from-manufacturer pricing with no distributor markup. Bulk and custom conjugation options available.

Common Research Applications

RAS/RAF mutation profiling: Validate KRAS/NRAS/BRAF mutation status using our antibodies (WB, IHC) alongside recombinant mutant proteins as assay controls for anti-EGFR therapy eligibility assessment.
MSI/dMMR screening: Apply our four-marker MMR IHC panel (MLH1, MSH2, MSH6, PMS2) on FFPE CRC tissue to identify patients eligible for immune checkpoint inhibitor therapy.
Post-surgical surveillance: Use CEA antibodies and ELISA kits for serial monitoring of circulating CEA levels in CRC patients after curative resection.
Immunotherapy biomarker discovery: Profile PD-L1 expression and tumor-infiltrating lymphocytes using our checkpoint antibody panel to stratify CRC patients for immunotherapy trials.

Documents & QC Data

Download product datasheets, validation images (WB/IHC/IF/FC), CoA, and application protocols on each product page. All data is lot-specific.

FAQs

Do you offer a complete MMR/MSI IHC panel?

Yes. We offer antibodies for all four MMR proteins — MLH1, MSH2, MSH6, and PMS2 — for IHC assessment of mismatch repair deficiency in CRC FFPE tissue. These are research use only.

Which KRAS antibodies do you carry?

We offer both polyclonal anti-KRAS antibodies that detect wild-type and common mutant forms, as well as recombinant KRAS proteins (wild-type and G12C/G12D/G12V) as assay controls.

Can your CEA reagents be used for ELISA development?

Yes. Multiple anti-CEA/CEACAM5 clones available: 1A088, 1A089 (ELISA, IHC, WB), SAA1208 (ELISA, FC, IF, WB), BW250/183 (FC; FITC/APC/PE/PerCP conjugates). Recombinant CEA proteins also available.

Do you have reagents for HER2-positive CRC?

Yes — HER2 amplification in CRC (~3%) is targetable with trastuzumab + pertuzumab. We offer anti-HER2 antibodies (IHC, WB) and biosimilar-grade reference proteins for comparability studies.

Can I get custom antibodies for novel targets?

Yes — our parent company AtaGenix provides full custom antibody development from immunogen design through hybridoma production and characterization, including targets not yet in our catalog.